$ASML

Stocks making the biggest moves midday: ASML, SK Hynix, SAP, Forte Bio, Brown-Forman & more

Midday movers included ASML down 8% after reports of China mass-producing domestically made deep UV chipmaking tools. SK Hynix, SanDisk and Micron fell, while CXMT surged after IPO. SAP rose over 7% on a second 10 billion-euro buyback tranche. Forte Bio jumped on Argenx’s $2.2B cash offer. Chevron and Exxon fell with oil; Baker Hughes rose on better Q2 results.

Original reporting
Published Jul 27, 2026, 6:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 27, 2026, 6:03 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Stocks making the biggest moves midday: ASML, SK Hynix, SAP, Forte Bio, Brown-Forman & more — source image
Decision brief

The 30-second read

$ASMLBearishMed
01

Why it matters

The most tradable items are the SAP buyback tranche start, Forte Biosciences acquisition terms, Baker Hughes earnings beat, and Rivian’s analyst upgrade. Other names are driven by sector narratives (ASML, SK Hynix) or pre/post-event positioning (Amkor, D-Wave).

02

Market read

Multiple same-day, company-specific catalysts are cited, creating actionable intraday-to-near-term trading opportunities, especially around M&A, buybacks, earnings, and analyst rating changes.

03

What to watch

For M&A and buyback stories, traders should watch deal-close conditions, financing details, and whether guidance or regulatory risks change the probability-weighted outcome.

Relevance 7/10Novelty 6/10Timing: midday moves with same-day catalysts (buyback start, M&A agreement, analyst upgrade, earnings beat, pre-earnings setup)

Background

This is a midday market-movers roundup citing specific catalysts across semiconductors, software buybacks, biotech M&A, energy geopolitics, and company-specific earnings/partnership/analyst actions.

Company-level read

Ticker impact

$ASMLBearishMedium confidence
Context

ASML slid 8% after a report said China began mass production of domestically made deep-UV chipmaking tools.

Expected impact

Near-term downside bias while the China competitive threat narrative spreads.

Evidence & confidence

The article ties ASML’s midday drop directly to a China mass-production development, which can pressure expectations for future tool orders.

$SAPBullishHigh confidence
Context

SAP ADRs jumped more than 7% after it said it would start the second part of a 10 billion-euro buyback tranche.

Expected impact

Supportive bias for the stock over the following sessions as traders price in the buyback execution.

Evidence & confidence

The article cites a specific, attributable corporate action and links it directly to the ADR’s move.

$FBRXBullishHigh confidence
Context

Forte Biosciences rallied about 40% after agreeing to be acquired by Argenx for $2.2 billion in cash.

Expected impact

Likely continued outperformance versus market until deal-close risks emerge; volatility around deal headlines.

Evidence & confidence

The article provides deal price, premium, and expected close timing, which are primary drivers for takeover spreads.

$ARGXNeutralLow confidence
Context

Argenx shares were down about 2% after it agreed to acquire Forte Biosciences for $2.2 billion in cash.

Expected impact

Near-term range-bound to slightly negative until financing and synergy details are clarified.

Evidence & confidence

The article reports the immediate move but does not provide financing structure or synergy assumptions.

$RIVNBullishMedium confidence
Context

Rivian popped 5% after Piper Sandler upgraded it to overweight from neutral with a $20 price target.

Expected impact

Short-term upside bias while upgrade-driven flows persist; watch for follow-through versus broader EV tape.

Evidence & confidence

The catalyst is explicit and same-day, but it is still an analyst action rather than a company fundamental print.

$BKRBullishMedium confidence
Context

Baker Hughes rose about 6% after posting better-than-expected Q2 earnings and revenue and reiterating guidance progress.

Expected impact

Sustained strength possible if investors extend the beat into full-year expectations.

Evidence & confidence

The article cites beat and a management quote about reaching guidance midpoint, which is actionable for near-term positioning.

$AMKRBearishLow confidence
Context

Amkor Technology shares dropped 7% as it gets set to report quarterly results after the market closes.

Expected impact

Directionally uncertain; elevated volatility into the after-hours earnings release.

Evidence & confidence

The article provides timing (after close) and the move, but no earnings expectations or new guidance.

$QBTSBullishLow confidence
Context

D-Wave Quantum shares added 5% after announcing a partnership with AT&T to use its annealing quantum computers for AI efforts.

Expected impact

Near-term momentum likely, but follow-through depends on contract size and measurable outcomes.

Evidence & confidence

The article mentions a partnership but provides no financial terms or performance milestones.

Market effects

Semiconductor equipment and memory complex show sensitivity to China localization and competitive narratives; biotech M&A premium supports deal appetite.

China-related semiconductor tooling news drives cross-border read-through into US-listed semis and memory names.

Energy names react to US-Iran attack pause, while telecom and quantum partnerships highlight ongoing AI infrastructure investment themes.

Counterpoint

Some moves may be positioning-driven (sector-wide memory IPO read-through, pre-earnings de-risking) rather than durable fundamentals.

Key entities

  • ASML

    Semiconductor equipment maker cited as down 8% on China mass production of domestically made deep-UV chipmaking tools.

  • SAP

    German software company cited as up 7% on starting the second part of a 10 billion-euro buyback.

  • Forte Biosciences

    Biotech cited as up about 40% on agreeing to be acquired by Argenx for $2.2 billion cash.

  • Argenx

    Acquirer cited as down about 2% after agreeing to buy Forte Biosciences.

  • Baker Hughes

    Energy services company cited as up about 6% after better-than-expected Q2 earnings and revenue.

Related articles

$RIVNMedAI 8/10

Rivian Earnings Call Shows Strong Growth, Lingering Losses - TipRanks.com

Rivian Automotive held its Q2 earnings call, citing strong early demand for the R2 and narrowing automotive gross loss. Q2 revenue rose to $1.66B (+27% YoY), with automotive revenue $1.14B and automotive gross loss of $36M. Software and services revenue was $515M (+37%). Management raised 2026 delivery guidance to 65,000-70,000 and trimmed 2026 CapEx to $1.7-$1.8B at midpoint, while adjusted EBITDA loss remained large.

$QBTSMed

D-Wave’s $550M Quantum Computing Bet Makes Error Correction 10X Cheaper

D-Wave says a Nature peer-reviewed paper shows its dual-rail erasure qubits can entangle with low error rates, enabling cheaper quantum error correction. It reports ~500 ns gate time, ~0.5% photon loss (erasure), ~0.1% phase errors, and ~1 in 1,000,000 bit-flips, with ~99.9% two-qubit fidelity. D-Wave also reported Q2 results: $3.1M quarterly revenue, $35.5M first-half bookings, $40.7M backlog, and a $48M net loss.

$QBTSMed

D-Wave Quantum Q2 Earnings Call Highlights

D-Wave Quantum reported a wider adjusted EBITDA loss of $37.1 million for Q2, citing higher personnel spending. GAAP gross profit fell 14% to $1.7 million, with gross margin down to 55.4%. First-half 2026 revenue was $5.9 million, down 67%, while bookings rose to $35.5 million and backlog reached $40.7 million. The company also discussed QCaaS production deployments and gate-model roadmap after its Quantum Circuits acquisition.

$QBTSMed

Why D-Wave Quantum Stock Just Fell

D-Wave Quantum Inc. shares (QBTS) fell about 9.3% after its Q2 report missed Wall Street expectations. Revenue was $3.1 million versus $4.1 million expected, and net loss was $0.13 per share versus $0.09 expected. Operating expenses rose 93% to $55 million, and adjusted EBITDA loss widened 85% to $37.1 million. Cash was $546.2 million.